fb tracking

Misprescribing and Overprescribing of Drugs

From WorstPills.org

The numbers are staggering: in 2003, an estimated 3.4 billion prescriptions were filled in retail drugstores and by mail order in the United States. That averages out to 11.7 prescriptions filled for each of the 290 million people in this country.1 But many people do not get any prescriptions filled in a given year, so it is also important to find out how many prescriptions are filled by those who fill one or more prescriptions. In a study based on data from 2000, more than twice as many prescriptions were filled for those 65 and older (23.5 prescriptions per year) than for those younger than 65 (10.1 prescriptions per year).2 Another way of looking at the high rate of prescriptions among older people is the government finding that although Medicare beneficiaries comprise only 14% of the community population, they account for more than 41% of prescription medicine expenses.3

There is no dispute that for many people, prescriptions are beneficial, even lifesaving in many instances. But hundreds of millions of these prescriptions are wrong, either entirely unnecessary or unnecessarily dangerous. Inappropriate prescribing is an academically gentle euphemism for prescriptions for which the risks outweigh the benefits, thus conferring a negative health impact on the patient. A recent comprehensive review of studies of such inappropriate prescribing in older patients found that 21.3% of community-dwelling patients 65 years or older were using at least one drug inappropriately prescribed. Much more so than age, per se, the total number of drugs being prescribed was an important predictor of inappropriate prescribing, as was female gender.4 Another study found that, conservatively—using very narrow criteria for inappropriate prescribing—elderly United States patients were prescribed at least one inappropriate drug at an estimated 16.7 million visits to physician offices or hospital outpatient departments in the year 2000.5 Examples of specific drugs that have been inappropriately prescribed, including studies involving younger adults and children, are given later in this section.

At the very least, misprescribing wastes tens of billions of dollars, barely affordable by many people who pay for their own prescriptions. But there are much more serious consequences. As discussed in Adverse Drug Reactions, more than 1.5 million people are hospitalized and more than 100,000 die each year from largely preventable adverse reactions to drugs that should not have been prescribed as they were in the first place.6 What follows is a summary of the seven all-too-often-deadly sins of prescribing.

First: The “disease” for which a drug is prescribed is actually an adverse reaction to another drug, masquerading as a disease but unfortunately not recognized by doctor and patient as such. Instead of lowering the dose of the offending drug or replacing it with a safer alternative, the physician adds a second drug to the regimen to “treat” the adverse drug reaction caused by the first drug. Examples discussed on this web site (see later in this section and in Drug-Induced Diseases) include drug-induced parkinsonism, depression, sexual dysfunction, insomnia, psychoses, constipation, and many other problems.

Second: A drug is used to treat a problem that, although in some cases susceptible to a pharmaceutical solution, should first be treated with commonsense lifestyle changes. Problems such as insomnia and abdominal pain often have causes that respond very well to nondrug treatment, and often the physician can uncover these causes by taking a careful history. Other examples include medical problems such as high blood pressure, mild adult-onset diabetes, obesity, anxiety, and situational depression. Doctors should recommend lifestyle changes as the first approach for these conditions, rather than automatically reach for the prescription pad.

Third: The medical problem is both self-limited and completely unresponsive to treatments such as antibiotics or does not merit treatment with certain drugs. This is seen most clearly with viral infections such as colds and bronchitis in otherwise healthy children or adults.

Fourth: A drug is the preferred treatment for the medical problem, but instead of the safest, most effective—and often least expensive—treatment, the physician prescribes one of the Do Not Use drugs listed on this web site or another, much less preferable alternative. An example of a less preferable alternative would be a drug to which the patient has a known allergy that the physician did not ask about.

Fifth: Two drugs interact. Each on its own may be safe and effective, but together they can cause serious injury or death.

Sixth: Two or more drugs in the same therapeutic category are used, the additional one(s) not adding to the effectiveness of the first but clearly increasing the risk to the patient. Sometimes the drugs come in a fixed combination pill, sometimes as two different pills. Often heart drugs or mind-affecting drugs are prescribed in this manner.

Seventh: The right drug is prescribed, but the dose is dangerously high. This problem is seen most often in older adults, who cannot metabolize or excrete drugs as rapidly as younger people. This problem is also seen in small people who are usually prescribed the same dose as that prescribed to people weighing two to three times as much as they do. Thus, per pound, they are getting two to three times as much medicine as the larger person.

Evidence of Misprescribing and Overprescribing

Here are some examples from recent studies by a growing number of medical researchers documenting misprescribing and overprescribing of specific types of drugs:

Treating Adverse Drug Reactions with More Drugs

Researchers at the University of Toronto and at Harvard have clearly documented and articulated what they call the prescribing cascade. It begins when an adverse drug reaction is misinterpreted as a new medical condition. Another drug is then prescribed, and the patient is placed at risk of developing additional adverse effects relating to this potentially unnecessary treatment.7 To prevent this prescribing cascade, doctors—and patients—should follow what we call Rule 7 of the Ten Rules for Safer Drug Use (see Protecting Yourself and Your Family from Preventable Drug-induced Injury): Assume that any new symptom you develop after starting a new drug might be caused by the drug. If you have a new symptom, report it to your doctor.

Some of the instances of the prescribing cascade that these and other researchers have documented include:

  • The increased use of anti-Parkinson’s drugs to treat drug-induced parkinsonism caused by the heartburn drug metoclopramide7 (REGLAN) or by some of the older antipsychotic drugs.
  • A sharply increased use of laxatives in people with decreased bowel activity that has been caused by antihistamines such as diphenhydramine (BENADRYL), antidepressants such as amitriptyline (ELAVIL)—a Do Not Use drug—or some antipsychotic drugs such as thioridazine (MELLARIL).8
  • An increased use of antihypertensive drugs in people with high blood pressure that was caused or increased by very high doses of nonsteroidal anti-inflammatory drugs (NSAIDs), used as painkillers or for arthritis.9
  • Failing to Treat Certain Problems with Nondrug Treatments

    Research has shown that many doctors are too quick to pull the prescription trigger. In one study, in which doctors and nurse practitioners were presented with part of a clinical scenario—as would occur when first seeing a patient with a medical problem—and then encouraged to ask to find out more about the source of the problem, 65% of doctors recommended that a patient complaining of insomnia be treated with sleeping pills even though, had they asked more questions about the patient, they would have found that the patient was not exercising, was drinking coffee in the evening, and, although awakening at 4 a.m., was actually getting seven hours of sleep by then.10

    In a similar study, doctors were presented with a patient who complained of abdominal pain and whose endoscopy showed diffuse irritation in the stomach. Sixty-five percent of the doctors recommended treating the problem with a drug—a histamine antagonist (such as Zantac, Pepcid, or Tagamet). Had they asked more questions they would have discovered that the patient was using aspirin, drinking a lot of coffee, smoking cigarettes, and was under considerable emotional stress—all potential contributing factors to abdominal pain and stomach irritation.

    In summarizing the origin of this overprescribing problem, the authors stated: “Apparently quite early in the formulation of the problem, the conceptual focus [of the doctor] appears to shift from broader questions like ‘What is wrong with this patient?’or ‘What can I do to help?’ to the much narrower concern, ‘Which prescription shall I write?’” They argued that this approach was supported by the “barrage” of promotional materials that only address drug treatment, not the more sensible lifestyle changes to prevent the problem.11

    In both of the above scenarios, nurse practitioners were much more likely than doctors to take an adequate history that elicited the causes of the problems and, not surprisingly, were only one-third as likely as the doctors to decide on a prescription as the remedy instead of suggesting changes in the patient’s habits.

    Throughout this web site, in the discussions about insomnia, high blood pressure, situational depression, mild adult-onset diabetes, and other problems, you will find out about the proven-effective nondrug remedies that should first be pursued before yielding to the riskier pharmaceutical solutions.

    Treating Viral Infections with Antibiotics or Treating Other Diseases with Drugs That Are Not Effective for Those Problems

    Two recently published studies, based on nationwide data from office visits for children and adults, have decisively documented the expensive and dangerous massive overprescribing of antibiotics for conditions that, because of their viral origin, do not respond to these drugs. Forty-four percent of children under 18 years old were given antibiotics for treatment of a cold and 75% for treatment of bronchitis. Similarly, 51% of people 18 or older were treated with antibiotics for colds and 66% for bronchitis. Despite the lack of evidence of any benefit for most people from these treatments, more than 23 million prescriptions a year were written for colds, bronchitis, and upper respiratory infections. This accounted for approximately one-fifth of all prescriptions for antibiotics written for children or adults.12, 13 An accompanying editorial warned of “increased costs from unnecessary prescriptions, adverse drug reactions, and [subsequent] treatment failures in patients with antibiotic-resistant infections” as the reasons to try to reduce this epidemic of unnecessary antibiotic prescribing.14

    Similar misprescribing of a drug useful and important for certain problems, but not necessary or effective, and often dangerous, for other problems can be seen in another recent study. In this case, 47% of the people admitted to a nursing home who were taking digoxin, an important drug for treating an abnormal heart rhythm called atrial fibrillation or for treating severe congestive heart failure, did not have either of these medical problems and were thereby being put at risk for life-threatening digitalis toxicity without the possibility of any benefit.15

    A final example in this category involves the overuse of a certain of drugs, in this case calcium channel blockers, which have not been established as effective for treating people who have had a recent heart attack. The study shows that this prescribing pattern actually did indirect damage to patients because their use was replacing the use of beta-blockers, drugs shown to be very effective for reducing the subsequent risk of death or hospitalization following a heart attack. Use of a calcium channel blocker instead of a beta-blocker was associated with a doubled risk of death, and beta-blocker recipients were hospitalized 22% less often than nonrecipients.16

    The Causes of Misprescribing and Overprescribing

    The Drug Industry

    The primary culprit in promoting the misprescribing and overprescribing of drugs is the pharmaceutical industry, which now sells about $216 billion worth of drugs in the United States alone.1 The industry uses loopholes in the law not requiring proof of superiority over existing drugs for approval, and otherwise intimidates the Food and Drug Administration (FDA) into approving record numbers of me-too drugs (drugs that offer no significant benefit over drugs already on the market) that often have dangerous adverse effects. In addition, the industry spends well in excess of $21 billion a year to promote drugs17 using advertising and promotional tricks that push at or through the envelope of being false and misleading. This industry has been extremely successful in distorting, in a profitable but dangerous way, the rational processes for approving and prescribing drugs. Two studies of the accuracy of ads for prescription drugs widely circulated to doctors both concluded that a substantial proportion of these ads contained information that was false or misleading and violated FDA laws and regulations concerning advertising.18, 19

    The fastest-growing segment of drug advertising is directed not at doctors but at patients. It has been estimated that from 1991 to 2002 DTC (direct-to-consumer) advertising expenditures in the United States grew from about $60 million a year to $3 billion a year,17 an increase of 50-fold in just eleven years, employing misleading advertising campaigns similar to those used for doctors. A study by Consumer Reports of 28 such ads found that “only half were judged to convey important information on side effects in the main promotional text,” only 40% were “honest about efficacy and fairly described the benefits and risks in the main text,” and 39% of the ads were considered “more harmful than helpful” by at least one reviewer.20 This campaign has been extremely successful. According to a drug industry spokesman, “There’s a strong correlation between the amount of money pharmaceutical companies spend on DTC advertising and what drugs patients are most often requesting from physicians.” The advertising “is definitely driving patients to the doctor’s office, and in many cases, leading patients to request the drugs by name.”21 The problems with DTC advertising are best summed up in an article written by a physician more than 15 years ago in the New England Journal of Medicine, before the current binge had really begun: “If direct [to consumer] advertising should prevail, the use of prescription medication would be warped by misleading commercials and hucksterism. The choice of a patient’s medication, even of his or her physician, could then come to depend more on the attractiveness of a full-page spread or prime-time commercial than on medical merit…such advertising would serve only the ad-makers and the media, and might well harm our patients.”22

    The Food and Drug Administration (FDA)

    Attempting to fend off FDA-weakening legislation even worse than that which was signed into law in 1997, the FDA has bent over backwards to approve more drugs, culminating in 1996 and 1997 when the agency approved a larger number than had ever been approved in any two-year period. Thousands of people were injured or killed after taking one of three such recently approved drugs (which have subsequently been recalled from the market). These drugs were the weight-loss drug dexfenfluramine (REDUX), the heart drug mibefradil (POSICOR), and the painkiller bromfenac (DURACT). Other drugs that would not have gotten approved in a more cautious era at the FDA have also been approved, but are likely either to be banned or to be forced to carry severe warnings that will substantially reduce their use. Many of these are included on this web site and listed as Do Not Use drugs.

    In the more than 30 years since the Public Citizen’s Health Research Group started monitoring the FDA and the drug industry, the current pro-industry attitude at the FDA is as bad and dangerous as it has ever been. In addition to record numbers of approvals of questionable drugs, FDA enforcement over advertising has all but disappeared. From a peak number of 157 enforcement actions to stop illegal prescription drug ads that understate risks and/or overstate benefits in 1998, the number has decreased to only 24—an 85% decrease—in 2003.23 There is no evidence that the accuracy or legality of these ads has increased during this interval, and the amount of such advertising has clearly increased. The division at FDA responsible for policing prescription drug advertising has never been given adequate resources to keep up with the torrent of newly approved drugs. More recently, however, it has also been thwarted by marching orders from higher up in the agency to, effectively, go easy on prescription drug advertising. As a result, the drug industry correctly believes it can get away with more violative advertising than in the past. The role of the United States Congress in pushing the FDA into approving more drugs, and passing, with the FDA’s reluctant approval, legislation to further weaken the FDA’s ability to protect the public, cannot be overlooked.


    The well-financed promotional campaigns by drug companies would not have as much of an impact as they do were there not such an educational vacuum about proper prescribing of drugs, a serious problem that must be laid at the feet of medical school and residency training. The varieties of overprescribing and misprescribing of drugs by doctors—the seven all-too-often-deadly sins of prescribing referred to above—are all strongly enhanced by the mind-altering properties of drug promotion. The best doctors, of whom there are many, do not waste their time talking to drug sales people, toss promotional materials away, and ignore drug ads in medical journals. Too many other doctors, however, are heavily influenced by drug companies, accepting free meals, free drinks, and free medical books in exchange for letting the drug companies “educate” them at symposia in which the virtues of certain drugs are extolled. Unfortunately, many of these doctors are too arrogant to realize that there is no such thing as a free lunch. The majority of doctors attending such functions have been found to increase their prescriptions for the targeted drugs following attendance at the “teach-in.”24

    Beyond traditional advertising and promotion and their influence, bias of drug-company-sponsored research, as published in medical journals, also can sway doctors toward more favorable impressions about drugs. An analysis was done of 56 trials that were paid for by drug companies and reported in 52 medical journals about drugs for arthritis and pain—NSAIDs. (These drug-company-sponsored studies represented 85% of those that the researchers originally looked at.) In studies identifying the company’s drug as less toxic than another drug, in barely one-half of the studies was there justification for the finding of less toxicity. This certainly explains why, contrary to fact, newer arthritis drugs almost always “seem” safer than older, usually much less expensive ones.25

    A final example demonstrates the ignorance of many physicians, especially in dealing with prescribing drugs to older adults. A study of physicians who treat Medicare patients found that 70% of the doctors who took an examination concerning their knowledge of prescribing for older adults failed to pass the test. The majority of physicians who were contacted for participation in the study refused to take the test, often giving as their reason that they had a “lack of interest in the subject.” The authors concluded “many of these physicians [who failed the exam] had…not made good use of the best information on prescribing for the elderly.”26


    A small fraction of pharmacists have, in our view, betrayed their professional ethics and are working for drug companies, engaging in such activities as calling doctors to get them to switch patients from drugs made by a company other than the one the pharmacist works for to the pharmacist’s employer’s drugs. In addition, pharmacy organizations such as the American Pharmaceutical Association and others have fought hard to prevent the FDA from requiring accurate patient package information to be dispensed with each prescription filled.

    Too many pharmacists, despite having computers to aid them, have been willing to fill prescriptions for pairs of drugs that, because of life-threatening adverse drug interactions if used at the same time, should never be dispensed to the same person.

    • Sixteen (32%) of 50 pharmacies in Washington, D.C., filled prescriptions for erythromycin and the now-banned terfenadine (SELDANE) without comment.27 These two drugs, if used in combination, can cause fatal heart arrhythmias.
    • In another study, of 245 pharmacists in seven cities, about one-third of pharmacists did not alert consumers to the potentially fatal and widely publicized interaction between Hismanal, a commonly used but now banned antihistamine, and Nizoral, an often-prescribed antifungal drug. Only 4 out of 17 pharmacists warned of the interaction between oral contraceptives and Rimactane, an antibiotic that could decrease the effectiveness of the oral contraceptive. Only 3 out of 61 pharmacists issued any verbal warnings about the interaction between Vasotec and Dyazide—two drugs for treating hypertension—which may lead to dangerously high levels of potassium in the blood.28
    • In yet another study, concurrent use of terfenadine (SELDANE) and contraindicated drugs declined over time. The rate of same-day dispensing declined by 84%, from an average of 2.5 per 100 persons receiving terfenadine in 1990 to 0.4 per 100 persons during the first six months of 1994, while the rate of overlapping use declined by 57% (from 5.4 to 2.3 per 100 persons). Most cases involved erythromycin. Despite substantial declines following reports of serious drug-drug interactions and changes in product labeling, concurrent use of terfenadine and contraindicated antibiotics such as erythromycin and clarithromycin (BIAXIN) and antifungals such as ketoconazole (NIZORAL) continued to occur.29
    • Patients

      For too many patients, the system is stacked against you—drug companies, doctors, and pharmacists are too often making decisions that ultimately derive from what is best for the drug companies, doctors, and pharmacists, and not necessarily from what is best for you. This web site has been researched and written to help you come out ahead in the struggle with our health care industry.

      In the sections on Adverse Drug Reactions and Drug-Induced Diseases, you can learn which common medical problems—depression, insomnia, sexual disorders, parkinsonism, falls and hip fractures, constipation, and many others—can actually be caused by drugs. Once you recognize these problems, you will be enabled to better take care of yourself and your family, and bring such problems to an end by discussing safer alternatives with your physician.

      On this web site, we list the drugs we and our consultants think you should not use. For each of these, we recommend safer alternatives. Each drug profile lists drug combinations that should not be used because of serious interactions.

      In Protecting Yourself and Your Family from Preventable Drug-induced Injury, we present a detailed strategy, beyond information on specific adverse effects and drugs, to help you to use drugs more safely, including Ten Rules for Safer Drug Use and how to use and maintain your own Drug Worksheet for Patient, Family, Doctor, and Pharmacist. This is your personalized plan for avoiding becoming a victim of overprescribing or misprescribing.

      Finally, in Saving Money When Buying Prescription Drugs, we discuss the latest information about generic drugs and show you how and why you can and should save hundreds of dollars a year or more. In short, this web site is intended to help you and your family to improve your health by using drugs, if necessary, more carefully and recognizing those you should avoid.


      Like what you’ve seen?

      Subscribe to WorstPills.org | Learn more about WorstPills.org

    • 1 Ukens C. How mail order pharmacy gained in market share in 2003. 2004. p.148.
    • 2 Stagnitti M.N. Trends in outpatient prescription drug utilization and expenditures,1997-2000: AHRQ Statistical Brief # 21. http://www.meps.ahrq.gov/papers/st21/stat21.htm. 2004.

    • 3 Stagnitti M.N, Miller G.E.,Moeller J.F. Outpatient prescription drug expenses, 1999: MEPS Chartbook No. 12, ARHQ Pub. No. 04-0001. 2003, Rockville, MD: Agency for Healthcare Research and Quality.
    • 4 Liu G.G.,Christensen D.B. The continuing challenge of inappropriate prescribing in the elderly: An update of the evidence. Journal of the American Pharmaceutical Association. 2002;42(6):847-857. PM:12482007.
    • 5 Goulding M.R. Inappropriate medication prescribing for elderly ambulatory care patients. Archives of Internal Medicine. 2004;164(3):305-312. PM:14769626.
    • 6 Lazarou J., Pomeranz B.H.,Corey P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. Journal of the American Medical Association. 1998;279(15):1200-1205. PM:9555760.
    • 7 Rochon P.A.,Gurwitz J.H. Optimising drug treatment for elderly people: The prescribing cascade. British Medical Journal. 1997;315(7115):1096-1099. PM:9366745.
    • 8 Monane M., Avorn J., Beers M.H., Everitt D.E. Anticholinergic drug use and bowel function in nursing home patients. Archives of Internal Medicine. 1993;153(5):633-638. PM:8439226.
    • 9 Rochon P.A.,Gurwitz J.H. Drug therapy. The Lancet. 1995;346(8966):32-36. PM:7603146.
    • 10 Everitt D.E., Avorn J.,Baker M.W. Clinical decision-making in the evaluation and treatment of insomnia. American Journal of Medicine. 1990;89(3):357-362. PM:2393038.
    • 11 Avorn J., Everitt D.E.,Baker M.W. The neglected medical history and therapeutic choices for abdominal pain: A nationwide study of 799 physicians and nurses. Archives of Internal Medicine. 1991;151(4):694-698. PM:2012450.
    • 12 Gonzales R., Steiner J.F.,Sande M.A. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. Journal of the American Medical Association. 1997;278(11):901-904. PM:9302241.
    • 13 Nyquist A.C., Gonzales R., Steiner J.F., Sande M.A. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. Journal of the American Medical Association. 1998;279(11):875-877. PM:9516004.
    • 14 Schwartz B., Mainous A.G. III,Marcy S.M. Why do physicians prescribe antibiotics for children with upper respiratory tract infections? Journal of the American Medical Association. 1998;279(11):881-882. PM:9516007.
    • 15 Aronow W.S. Prevalence of appropriate and inappropriate indications for use of digoxin in older patients at the time of admission to a nursing home. Journal of the American Geriatric Society. 1996;44(5):588-590. PM:8617911.
    • 16 Soumerai S.B., McLaughlin T.J., Spiegelman D., et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. Journal of the American Medical Association. 1997;277(2):115-121. PM:8990335.
    • 17 2003
    • 18 Stryer D.,Bero L.A. Characteristics of materials distributed by drug companies: An evaluation of appropriateness. Journal of General Internal Medicine. 1996;11(10):575-583. PM:8945688.
    • 19 Wilkes M.S., Doblin B.H.,Shapiro M.F. Pharmaceutical advertisements in leading medical journals: Experts’ assessments. Annals of Internal Medicine. 1992;116(11):912-919. PM:1580449.
    • 20 Drug advertising: Is this good medicine? Consumer Reports. 1996;61(6):62-63. PM:10182464.
    • 21 The top 200 drugs. 1998. p.46-53.
    • 22 Cohen E.P. Direct-to-the-public advertisement of prescription drugs. New England Journal of Medicine. 1988;318(6):373-376. PM:3123930.
    • 23 2004
    • 24 1990
    • 25 Rochon P.A., Gurwitz J.H., Simms R.W., et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine. 1994;154(2):157-163. PM:8285810.
    • 26 Ferry M.E., Lamy P.P.,Becker L.A. Physicians’ knowledge of prescribing for the elderly: A study of primary care physicians in Pennsylvania. Journal of the American Geriatric Society. 1985;33(9):616-625. PM:4031340.
    • 27 Cavuto N.J., Woosley R.L.,Sale M. Pharmacies and prevention of potentially fatal drug interactions. Journal of the American Medical Association. 1996;275(14):1086-1087. PM:8601923.
    • 28 Headden S. Danger at the Drugstore. 1996. p.46-53.
    • 29 Thompson D.,Oster G. Use of terfenadine and contraindicated drugs. Journal of the American Medical Association. 1996;275(17):1339-1341. PM:8614120.